Stan discusses the challenges of allocating to high-performing funds while grappling with high fees, revealing the importance of EROC in their decision-making process. He shares insights from their pioneering journey into alternative investments, including life settlements and clinical trials, in pursuit of uncorrelated returns. Despite the allure of these strategies, capacity limitations and market saturation pose ongoing challenges for maintaining significant allocations.
